Aligos Therapeutics price to book ratio ALGS

Market value divided by the book value of the company's net assets, since 2021.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 0.5×; Jul 2026
6-year median: 0.5×
6-year range: 0.1× to 6.6×

Aligos Therapeutics' price to book ratio is not a meaningful number today: no cover page share count was public by this date.

It was last meaningful in Jul 2026, at 0.5×.

On the days it had one over the last 6 years, its median was 0.5×, from 0.1× in May 2025 to 6.6× in Jun 2021.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	0.5×	0.3×	0.7×
2025	0.5×	0.1×	3.1×
2024	2.9×	0.3×	2.9×
2023	0.9×	0.4×	1.0×
2022	0.3×	0.3×	0.8×
2021	2.3×	2.3×	6.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Aligos Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.